CRUSE Control Urticaria app analytics for December 9

CRUSE Control Urticaria

CRUSE Control Urticaria

  • Moxie GmbH
  • Apple App Store
  • Free
  • Medical
CRUSE® is an APP developed by renowned dermatologists and allergoligists to help patients with Chronic Urticaria manage their condition. Take control of your Chronic Urticaria by recording your symptoms and impact on your quality of life in just a few minutes each day. Track how you respond to treatment and how it can be improved by using CRUSE in cooperation with your treating physician. Over 50 million people worldwide have Chronic Urticaria. It is a common condition that causes itchy wheals and/or swellings (angioedema) and can be very debilitating. To ensure optimal treatment, continuous monitoring and documentation of disease activity is essential. From now on, CRUSE® will take care of this for you. Your UCARE Team - With more than 130 member centres in 41 countries, GA²LEN’s Urticaria Centres of Reference and Excellence (UCARE network) is the biggest and most active consortium of urticariologists and urticaria centres. Are you a physician? Find out more on www.cruse-control-com
CRUSE Control Urticaria

Store Rank

The Store Rank is based on multiple parameters set by Google and Apple.

All Categories in
United States--
Medical in
United States--
Create an account to see avg.monthly downloadsContact us

CRUSE Control Urticaria Ranking Stats Over Time

Similarweb's Usage Rank & Apple App Store Rank for CRUSE Control Urticaria

Rank

No Data Available

CRUSE Control Urticaria Ranking by Country

Counties in which CRUSE Control Urticaria has the highest ranking in its main categories

No Data to Display

Top Competitors & Alternative Apps

Apps with a high probability of being used by the same users, from the same store.

DermaValue

DermaValue

SWISS4WARD EUROPE SL

EADV Congress 2024

EADV Congress 2024

JMarquardt Technologies GmbH

ASBAI

ASBAI

GN1 SISTEMAS E PUBLICACOES LTDA - EPP

MASK-air

MASK-air

MASK-AIR

CRUSE Control Urticaria VS.

December 9, 2024